Business Description
Moleculin Biotech Inc
NAICS : 325412
SIC : 2834
ISIN : US60855D1019
Description
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 18.59 | |||||
| Equity-to-Asset | 0.32 | |||||
| Debt-to-Equity | 0.07 | |||||
| Debt-to-EBITDA | -0.02 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 1/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 20.4 | |||||
| 3-Year EPS without NRI Growth Rate | 21.3 | |||||
| 3-Year FCF Growth Rate | 23.6 | |||||
| 3-Year Book Growth Rate | -20.3 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 36.27 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 14-Day RSI | 37.65 | |||||
| 12-1 Month Momentum % | -26.5 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.08 | |||||
| Quick Ratio | 2.08 | |||||
| Cash Ratio | 1.68 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -42.5 | |||||
| Shareholder Yield % | -70.79 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -139.61 | |||||
| ROA % | -95.68 | |||||
| ROIC % | -241.69 | |||||
| ROC (Joel Greenblatt) % | -3967.62 | |||||
| ROCE % | -111.13 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 0.73 | |||||
| EV-to-EBIT | 0.12 | |||||
| EV-to-Forward-EBIT | -6.27 | |||||
| EV-to-EBITDA | 0.12 | |||||
| EV-to-Forward-EBITDA | -7.05 | |||||
| EV-to-FCF | 0.14 | |||||
| Earnings Yield (Greenblatt) % | 833.33 | |||||
| FCF Yield % | -416.43 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Moleculin Biotech Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -10.778 | ||
| Beta | 1.64 | ||
| Volatility % | 61.04 | ||
| 14-Day RSI | 37.65 | ||
| 14-Day ATR (€) | 0.000007 | ||
| 20-Day SMA (€) | 6.45 | ||
| 12-1 Month Momentum % | -26.5 | ||
| 52-Week Range (€) | 5.489999 - 12.749999 | ||
| Shares Outstanding (Mil) | 3.19 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Moleculin Biotech Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Moleculin Biotech Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Moleculin Biotech Inc Frequently Asked Questions
What is Moleculin Biotech Inc(FRA:MOL)'s stock price today?
The current price of FRA:MOL is €6.45. The 52 week high of FRA:MOL is €12.75 and 52 week low is €5.49.
When is next earnings date of Moleculin Biotech Inc(FRA:MOL)?
The next earnings date of Moleculin Biotech Inc(FRA:MOL) is 2025-03-21 Est..
Does Moleculin Biotech Inc(FRA:MOL) pay dividends? If so, how much?
Moleculin Biotech Inc(FRA:MOL) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers